Physician profile
Darshan Patel
NPI 1336466200
$1,922.50
in general payments reported to CMS, 2019-2025
28 companies · $69.23 in 2025
The $69.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.64 · 2020: $78.85 · 2021: $144 · 2022: $349 · 2023: $544 · 2024: $655 · 2025: $69.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $324.53 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $277.26 | 2022-2025 | |
| Lilly USA, LLC | $224.98 | 2020-2024 | Mounjaro, Zepbound, Amyvid |
| Lexicon Pharmaceuticals, INC. | $145.85 | 2023 | Inpefa |
| Pfizer INC. | $124.58 | 2023-2025 | |
| Amgen INC. | $121.46 | 2022-2023 | Otezla, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $96.21 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $65.73 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.79 | 2019-2020 | |
| Astellas Pharma US INC | $55.29 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $48.91 | 2023-2024 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $44.53 | 2021-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $44.44 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.58 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $25.15 | 2024 | Watchman Flx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.82 | 2022 | |
| Braemar Manufacturing, LLC | $20.53 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.32 | 2025 | Gvoke Hypopen |
| Organon LLC | $19.10 | 2023 | Nexplanon |
| Mallinckrodt Hospital Products INC. | $18.71 | 2024 | Terlivaz |
| Smith+Nephew, INC. | $17.82 | 2022 | |
| Mylan Specialty L.P. | $16.70 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.51 | 2020 | |
| Abbott Laboratories | $15.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.24 | 2023 | Farxiga |
| Ironwood Pharmaceuticals, INC | $15.04 | 2022 | |
| Tandem Diabetes Care, INC. | $14.27 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.